- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03367156
Dexamethasone in Controlling Dyspnea in Patients With Cancer
A Randomized Controlled Trial of Dexamethasone for Dyspnea in Cancer Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Compare the intensity of dyspnea (numeric rating scale [NRS]) in the dexamethasone arm with that in the placebo arm at week 1.
SECONDARY OBJECTIVES:
I. Compare the effects of dexamethasone with those of placebo in terms of personalized dyspnea response (based on a personalized dyspnea goal), unpleasantness of dyspnea, other symptoms, health-related quality of life, respiratory physiologic function, and adverse effects at week 1 and week 2, as well as the intensity of dyspnea at week 2.
II. Identify predictive markers of dyspnea response to dexamethasone.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive dexamethasone orally (PO) twice daily (BID) on days 1-28 in the absence of disease progression or unacceptable toxicity.
GROUP II: Patients receive placebo PO BID on days 1-14 and dexamethasone PO BID on days 15-28 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at days 28 and 42.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
Houston, Texas, United States, 77026
- Lyndon B. Johnson Hospital
-
Houston, Texas, United States, 77028
- Harris Health System Settegast Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of cancer.
- Dyspnea with an average intensity >= 4 on the dyspnea NRS (range 0-10) over the past week.
- Radiologic suspicion of thoracic involvement, such as primary or metastatic lung cancer, lymphangitic carcinomatosis, airway infiltration, lymphadenopathy, pleural or chest wall invasion.
- Seen at an outpatient clinic at MD Anderson Cancer Center or Lyndon B. Johnson (LBJ) Hospital General Oncology Clinic.
- Able to communicate in English or Spanish.
- Karnofsky performance status >= 30%.
Exclusion Criteria:
- Delirium (i.e., score > 13 on the Memorial Delirium Assessment Scale; range 1-30).
- Oxygen saturation < 90% despite supplemental oxygen > 6 L/minute.
- Previous allergic reactions to dexamethasone.
- Diagnosis of diabetes mellitus uncontrolled with oral hypoglycemic agents or insulin.
- Postsurgical open wound that has not healed at the time of enrollment.
- Any infection requiring antibiotics at the time of study enrollment.
- Major surgery within the past 2 weeks.
- Megestrol use at the time of study enrollment.
- Neutropenia (absolute neutrophil count < 1.0 x 10^9/L) at the time of study enrollment (bloodwork is not required if patient did not have chemotherapy within past 2 weeks).
- Currently receiving or expected to start cytotoxic chemotherapy or immunotherapy within 1 week of study enrollment and additional dexamethasone cannot be used concurrently as per attending oncologist.
- Severe anemia (hemoglobin < 8 g/L) not corrected prior to study enrollment (bloodwork is not required if patient did not have chemotherapy within past 2 weeks).
- Chronic obstructive pulmonary disease (COPD) exacerbation at the time of study enrollment.
- Heart failure exacerbation at the time of study enrollment.
- Expected to undergo therapeutic thoracentesis in the next 2 weeks.
- High anxiety score (>= 15/21) on the Hospital Anxiety and Depression Scale (HADS).
- Chronic systemic corticosteroid use (> 14 days) at the time of study enrollment.
- Any expected corticosteroid use during study enrollment at higher doses than will be used in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group I (dexamethasone)
Patients receive dexamethasone PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.
|
Ancillary studies
Given PO
Other Names:
|
Active Comparator: Group II (placebo, dexamethasone)
Patients receive placebo PO BID on days 1-14 and dexamethasone PO BID on days 15-28 in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
Ancillary studies
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Dyspnea Numeric Score Over the Past 24 Hours for Baseline and Day 7 Average Intensity
Time Frame: Baseline and Day 7
|
The average dyspnea intensity over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10.
The total score ranged from 0-10 where higher scores indicate worse dyspnea.
The change in Dyspnea scores between Baseline and Day 7 were measured.
Linear model analysis was used for analysis.
|
Baseline and Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Dyspnea Numeric Score Over the Past 24 Hours for Baseline and Day 14 Average Intensity
Time Frame: Baseline and Day 14
|
The average dyspnea intensity over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10.
The total score ranged from 0-10 where higher scores indicate worse dyspnea.
The change in Dyspnea scores between Baseline and Day 14 were measured.
Linear model analysis was used for analysis.
|
Baseline and Day 14
|
Change in Dyspnea Numeric Score Over the Past 24 Hours for Baseline and Day 7 Average Unpleasantness
Time Frame: Baseline and Day 7
|
The average dyspnea unpleasantness over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10.
The total score ranged from 0-10 where higher scores indicate worse dyspnea.
The change in Dyspnea unpleasantness scores between Baseline and Day 7 were measured.
Linear model analysis was used for analysis.
|
Baseline and Day 7
|
Change in Edmonton Symptom Assessment Scale (ESAS) Dyspnea Score Between Baseline and Day 7
Time Frame: Baseline and Day 7
|
ESAS (Edmonton Symptom Assessment Scale) is a validated scale ranging from 0 (not at all) to 10 (very much) used to assess 10 symptoms commonly experienced by cancer patients during the previous 24 hours: pain, fatigue, nausea, depression, anxiety, drowsiness, dyspnea, anorexia, sleep and feeling of well being.
The change in ESAS fatigue score between Baseline and Day 7 were measured.
Total ESAS fatigue score ranged from 0-10, with a higher score indicating higher fatigue.
Linear model analysis was used for analysis.
|
Baseline and Day 7
|
Change in European Organization for Research and Treatment of Cancer-Quality of Life (EORTC QLQ-C30) Dyspnea Score Between Baseline and Day 7
Time Frame: Baseline and Day 7
|
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is a well-validated quality-of-life assessment for patients with cancer, consisting of 30 questions that encompass three symptom scales (pain, fatigue, and nausea/vomiting) and six questions about single symptoms, as well as five functional scales (physical, cognitive, role, emotional, and social) and one scale assessing global health status/quality of life.
Each single symptoms have four response categories (1=not at all, and 4=very much).
The change in EORTC fatigue score between Baseline and Day 7 were measured.
Total scores using a complex scoring procedures ranges from 0 to 100 with a higher scores indicating higher fatigue.
Linear model analysis was used for analysis.
|
Baseline and Day 7
|
Change in Dyspnea Numeric Score Over the Past 24 Hours for Baseline and Day 14 Average Unpleasantness
Time Frame: Baseline and Day 14
|
The average dyspnea unpleasantness over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10.
The total score ranged from 0-10 where higher scores indicate worse dyspnea.
The change in Dyspnea unpleasantness scores between Baseline and Day 14 were measured.
Linear model analysis was used for analysis.
|
Baseline and Day 14
|
Change in Edmonton Symptom Assessment Scale (ESAS) Dyspnea Score Between Baseline and Day 14
Time Frame: Baseline and Day 14
|
ESAS (Edmonton Symptom Assessment Scale) is a validated scale ranging from 0 (not at all) to 10 (very much) used to assess 10 symptoms commonly experienced by cancer patients during the previous 24 hours: pain, fatigue, nausea, depression, anxiety, drowsiness, dyspnea, anorexia, sleep and feeling of well being.
The change in ESAS fatigue score between Baseline and Day 14 were measured.
Total ESAS fatigue score ranged from 0-10, with a higher score indicating higher fatigue.
Linear model analysis was used for analysis.
|
Baseline and Day 14
|
Change in European Organization for Research and Treatment of Cancer Quality of Life (EORTC) Dyspnea Score Between Baseline and Day 14
Time Frame: Baseline and Day 14
|
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is a well-validated quality-of-life assessment for patients with cancer, consisting of 30 questions that encompass three symptom scales (pain, fatigue, and nausea/vomiting) and six questions about single symptoms, as well as five functional scales (physical, cognitive, role, emotional, and social) and one scale assessing global health status/quality of life.
Each single symptoms have four response categories (1=not at all, and 4=very much).
The change in EORTC fatigue score between Baseline and Day 14 were measured.
Total scores using a complex scoring procedures ranges from 0 to 100 with a higher scores indicating higher fatigue.
Linear model analysis was used for analysis.
|
Baseline and Day 14
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Hui, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Respiration Disorders
- Signs and Symptoms, Respiratory
- Neoplasms
- Dyspnea
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Dermatologic Agents
- Dexamethasone
- Dexamethasone acetate
- BB 1101
- Ichthammol
Other Study ID Numbers
- 2017-0591 (Other Identifier: M D Anderson Cancer Center)
- NCI-2018-01129 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyspnea
-
Assistance Publique - Hôpitaux de ParisRecruitingDyspnea Invasive Mechanical Ventilation-associatedFrance
-
Mayo ClinicCompletedShortness of Breath | Cardiac; DyspneaUnited States
-
Qure Healthcare, LLCJohnson & Johnson Pharmaceutical Research & Development, L.L.C.CompletedDyspnea | Unexplained Chronic DyspneaUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedRelationship Between Dyspnea and Ventilatory VariabilityFrance
-
University of MonastirCompleted
-
University of California, Los AngelesNot yet recruitingShortness of Breath/Dyspnea
-
Assistance Publique - Hôpitaux de ParisRecruitingDyspnea and Respiratory Insufficiency in ChildrenFrance
-
Medical University of ViennaRecruitingEchocardiography | Acute DyspneaAustria
-
Intersection Medical, Inc.CompletedPulmonary Congestion | Dyspnea, | Acute Heart Failure SyndromeUnited States
-
University of MonastirCompletedDyspnea; CardiacTunisia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States